Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2006 | Original article

Evaluation of the pharmacokinetics of ⁶⁸Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for ⁹⁰Y-DOTATOC therapy

Authors: Sophia Koukouraki, Ludwig G. Strauss, Vassilios Georgoulias, Jochen Schuhmacher, Uwe Haberkorn, Nikolaos Karkavitsas, Antonia Dimitrakopoulou-Strauss

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2006

Abstract

Purpose

The purpose of the study was to evaluate the pharmacokinetics of ⁶⁸Ga-DOTATOC in order to ascertain which parameters have the greatest impact on the global DOTATOC standardised uptake value (SUV), defined as the mean SUV of the last frame of the dynamic study 55–60 min p.i.

Methods

Twenty-two patients with 74 metastatic lesions were examined with dynamic ⁶⁸Ga-DOTATOC PET studies. Standardised uptake values (SUVs) were calculated for all frames following the injection of the tracer. We defined global SUV as the mean SUV of the last frame (frame duration 5 min) of the dynamic study 55–60 min p.i. A two-tissue compartment model with a blood compartment was used for the evaluation of the rate constants k ₁ (receptor binding), k ₂ (displacement from the receptor), k ₃ (cellular internalisation), k ₄ (cellular externalisation) and fractional blood volume (V_b). Furthermore, a non-compartmental model was applied for calculation of the fractal dimension (FD) of the time-activity curves based on the box counting procedure.

Results

Qualitative analysis revealed increased uptake of ⁶⁸Ga-DOTATOC in 21/22 patients and in 72/74 lesions. The SUV for ⁶⁸Ga-DOTATOC was highly variable, with a range from 0.877 to 28.07 (mean 8.73). The highest uptake was measured in a patient with a NET of the pancreas and the lowest in a patient with a medullary thyroid carcinoma (MEN II). The quantitative evaluation based on the compartmental analysis revealed high receptor binding (k ₁) and internalisation (k ₃) for ⁶⁸Ga-DOTATOC, and low cellular externalisation (k ₄) as well as a relatively low fractional blood volume (V_b). The FD values varied from 1.10 to 1.45, with a mean of 1.33. No significant linear correlation was found for k ₁ and k ₃. A low, linear correlation was noted for k ₁ and V_b (r=0.25,p=0.03), and there was a significant non-linear correlation between SUV and FD (r=0.74, p<0.001). Best subset analysis demonstrated that k ₁ had the greatest impact on the global SUV, followed by V_b and k ₃.

Conclusion

DOTATOC uptake in NETs is mainly dependent on k ₁ (receptor binding) and V_b (fractional blood volume). Pharmacokinetic data analysis can help to separate blood background activity (V_b) from the receptor binding (k ₁), which may help to optimise planning of ⁹⁰Y-DOTATOC therapy.

Kaltsas G, Besser M, Grossman A. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458–511PubMedCrossRef

Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994;733:122–37PubMedCrossRef

Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623–48PubMed

Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, et al. Dynamic PET¹⁸F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001;42:713–20PubMed

Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79–83PubMedCrossRef

Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25:568–80PubMedCrossRef

De Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, et al. [DOTA⁰,TYR³] octreotide is dependent on the peptide amount. Eur J Nucl Med 1999;26:693–8PubMedCrossRef

De Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA⁰,d-Phe¹, Tyr³]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368–71PubMedCrossRef

Bohuslavizki KH, Brenner W, Braunsdorf WE, Behnke A, Tinnemeyer S, Hugo HH, et al. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun 1996;17:302–10PubMedCrossRef

10.

Maecke H, Hofmann M, Haberkorn U. 68-Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46:172S–8SPubMed

11.

Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971–94PubMed

12.

Kontaxakis G, Strauss LG, Thireou T, Ledesma-Carbayo MJ, Santos A, Pavlopoulos SA et al. Iterative image reconstruction for clinical PET using ordered subsets, median root prior, and a web-based interface. Mol Imaging Biol 2002;4:219–31PubMedCrossRef

13.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of (⁶⁸Ga)-DOTA-D-Phe¹-Tyr³-octreotide (DOTATOC) kinetics in patients with meningiomas J Nucl Med 2005;46:763–9PubMed

14.

Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med 1997;38:1818–23PubMed

15.

Ohtake T, Kosaka N, Watanabe T, Yokoyama I, Moritan T, Masuo M,, et al. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 1991;32:1432–8PubMed

16.

Dimitrakopoulou–Strauss A, Strauss LG, Mikolajczyk K, Burger C, Lehnert T, Bernd L, et al. On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med 2003;2:306–13

17.

Hofmann M, Maecke H, Börner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand⁶⁸Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7PubMedCrossRef

18.

Baish JW, Jain RK. Fractals and cancer. Cancer Res 2001;61:8347–50

19.

Majumdar S, Link TM, Millard J, Lin JC, Augat P, Newitt D, et al. In vivo assessment of trabecular bone structure using fractal analysis. Med Phys 2000;27:2594–9PubMedCrossRef

20.

Kuikka JT, Hartikainen P. Heterogeneity of cerebral blood flow: a fractal approach. Nuklearmedizin 2000;39:37–42PubMed

Title: Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy
Authors: Sophia Koukouraki
Ludwig G. Strauss
Vassilios Georgoulias
Jochen Schuhmacher
Uwe Haberkorn
Nikolaos Karkavitsas
Antonia Dimitrakopoulou-Strauss
Publication date: 01-04-2006
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-0006-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Evaluation of the pharmacokinetics of ⁶⁸Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for ⁹⁰Y-DOTATOC therapy

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2006

Molecular imaging of cell transplantation in Parkinson’s disease

Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes

Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033

Role of pre-operative imaging using 99mTc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy

The immune system and cancer: the evolving role of molecular imaging and molecular targeted therapy

Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours